Emily Chan

1.4k total citations · 2 hit papers
38 papers, 835 citations indexed

About

Emily Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Emily Chan has authored 38 papers receiving a total of 835 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 11 papers in Molecular Biology. Recurrent topics in Emily Chan's work include Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (13 papers) and CAR-T cell therapy research (7 papers). Emily Chan is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Lung Cancer Treatments and Mutations (13 papers) and CAR-T cell therapy research (7 papers). Emily Chan collaborates with scholars based in United States, Japan and Spain. Emily Chan's co-authors include Nuzhat Ahmed, George Kannourakis, Steven S. Raman, J. Randolph Hecht, Ruth M. Escalona, Dilys T.H. Leung, Marwan Fakih, Qui Tran, Chiara Cremolini and Jock K. Findlay and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Emily Chan

35 papers receiving 827 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

2023 163 citations Marwan Fakih, Lisa Salvatore et al. profile →
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial

2024 49 citations Yasutoshi Kuboki, Marwan Fakih et al. Nature Medicine profile →

Peers

Countries citing papers authored by Emily Chan

Since Specialization

Citations

This map shows the geographic impact of Emily Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Chan more than expected).

Fields of papers citing papers by Emily Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Chan. The network helps show where Emily Chan may publish in the future.

Co-authorship network of co-authors of Emily Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Chan. A scholar is included among the top collaborators of Emily Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Chan. Emily Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). 2025 ·Journal of Clinical Oncology ·Tae Won Kim, Timothy Price, (unknown), John H. Strickler, Toshiki Masuishi, (unknown), Şuayib Yalçın, (unknown), Emily Chan, (unknown), Yu Sunakawa	0
2	Biomarkers of emergent resistance to sotorasib plus panitumumab in KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study. 2025 ·Journal of Clinical Oncology ·Lisa Salvatore, Yuliya V. Katlinskaya, Abraham Anderson, Antreas Hindoyan, Amrita Pati, Marwan Fakih, Anita Reddy, Emily Chan, Lata Mukundan	0
3	Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study. 2024 ·Journal of Clinical Oncology ·Corey J. Langer, Rachel Galot, Hans Prenen, David S. Hong, Iván Victoria, Ravi Salgia, Maxime Chénard-Poirier, Muhammad Furqan, Emily Chan, (unknown), Caihong Xia, Bob T. Li	1
4	Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial breakdown → 2024 ·Nature Medicine ·Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Rona Yaeger, Toshiki Masuishi, Edward Kim, Christine M. Bestvina, Scott Kopetz, Gerald S. Falchook, Corey J. Langer, John C. Krauss, Sonam Puri, (unknown), Emily Chan, (unknown), Lata Mukundan, Abraham Anderson, Qui Tran, David S. Hong	49
5	Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC). 2024 ·Journal of Clinical Oncology ·Marwan Fakih, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Filippo Pietrantonio	7
6	A phase 1b study of sotorasib combined with panitumumab as second-line treatment of KRAS G12C-mutated colorectal cancer. 2024 ·Journal of Clinical Oncology ·Rona Yaeger, Corey J. Langer, J.C. Ruffinelli, Marwan Fakih, Muhammad Furqan, Jean‐Pascal Machiels, (unknown), (unknown), Emily Chan, Caihong Xia, Toshiki Masuishi	3
7	Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300. 2024 ·Journal of Clinical Oncology ·Dominik Paul Modest, Marwan Fakih, Lisa Salvatore, Taito Esaki, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Chiara Cremolini, Qui Tran, Emily Chan, Joseph Chao, István Májer, Filippo Pietrantonio	2
8	92MO Sotorasib (Soto) + panitumumab (Pmab) and FOLFIRI in previously treated KRASG12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy for CodeBreaK 101 phase Ib expansion cohort 2023 ·Annals of Oncology ·(unknown), (unknown), J-P. Machiels, David S. Hong, Richard Greil, Emily Chan, (unknown), (unknown), (unknown), (unknown), Yasutoshi Kuboki	2
9	437TiP Trial in progress: A phase III global study of sotorasib, a specific KRAS G12C inhibitor, in combination with panitumumab versus investigator’s choice in chemorefractory metastatic colorectal cancer (CodeBreaK 300) 2022 ·Annals of Oncology ·David Páez, Fausto Meriggi, Chiara Cremolini, Gunnar Folprecht, (unknown), Emily Chan, Qui Tran, Marwan Fakih	6
10	444TiP Trial in progress: A phase Ib study of sotorasib, a selective KRAS G12C inhibitor, in combination with panitumumab and FOLFIRI in treatment naïve and previously treated metastatic colorectal cancer (CodeBreaK 101) 2022 ·Annals of Oncology ·(unknown), Yasutoshi Kuboki, Marwan Fakih, John H. Strickler, Muhammad Furqan, (unknown), (unknown), Qui Tran, Emily Chan, David S. Hong	2
11	A phase 1b study of sotorasib, a specific and irreversible KRAS^G12Cinhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC) and other solid tumors (CodeBreaK 101). 2022 ·Journal of Clinical Oncology ·David S. Hong, Rona Yaeger, Yasutoshi Kuboki, Toshiki Masuishi, Minal Barve, Gerald S. Falchook, Ramaswamy Govindan, Davendra Sohal, Pashtoon Murtaza Kasi, Timothy F. Burns, Corey J. Langer, Sonam Puri, Emily Chan, Pegah Jafarinasabian, Gataree Ngarmchamnanrith, Marko Rehn, Qui Tran, David R. Gandara, John H. Strickler, Marwan Fakih	11
12	434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC) 2021 ·Annals of Oncology ·Marwan Fakih, Gerald S. Falchook, David S. Hong, Rona Yaeger, Emily Chan, Omar Mather, (unknown), Tian Dai, John H. Strickler	17
13	Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial 2021 ·Nature Medicine ·Reinhard Dummer, David Gyorki, John Hyngstrom, Adam C. Berger, Robert M. Conry, Lev Demidov, Anjali Sharma, Sheryl Treichel, Hoi-Shen Radcliffe, Kevin Gorski, Abraham Anderson, Emily Chan, Mark B. Faries, Merrick I. Ross	89
14	Early safety from a phase I, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into liver tumors in combination with pembrolizumab (pem). 2020 ·Journal of Clinical Oncology ·J. Randolph Hecht, Miklos Pless, Antonio Cubillo, Aitana Calvo, Hong Jae Chon, Chunxu Liu, Wendy Snyder, Emily Chan, Marya Chaney, Jason Chesney, Aleix Prat	8
15	Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells 2018 ·Seminars in Cancer Biology ·Nuzhat Ahmed, Ruth M. Escalona, Dilys T.H. Leung, Emily Chan, George Kannourakis	129
16	Latency to startle is reduced in the 5xFAD mouse model of Alzheimer’s disease 2018 ·Behavioural Brain Research ·Darren Story, Emily Chan, (unknown), Julien Rossignol, Gary Dunbar	6
17	A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318). 2018 ·Journal of Clinical Oncology ·J. Randolph Hecht, Aleix Prat, Miklos Pless, Antonio Cubillo, Aitana Calvo, Steven S. Raman, Jason Chesney, Chunxu Liu, Emily Chan	7
18	Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results 2017 ·Investigational New Drugs ·Dana B. Cardin, Laura W. Goff, Emily Chan, Jennifer G. Whisenant, Gregory D. Ayers, Naoko Takebe, Lori R. Arlinghaus, Thomas E. Yankeelov, Jordan Berlin, Nipun B. Merchant	16
19	Mouse Model for Lowe Syndrome/Dent Disease 2 Renal Tubulopathy 2010 ·Journal of the American Society of Nephrology ·(unknown), Emily Chan, Isa Bernardini, Yien–Ming Kuo, William A. Gahl, Robert L. Nussbaum	52
20	502 POSTER SNS-314, a selective Aurora kinase inhibitor with potent, pre-clinical antitumour activity, shows broad therapeutic potential in combination with standard chemotherapeutics and synergy with microtubule targeted agents 2007 ·European Journal of Cancer Supplements ·Emily Chan, Raymond V. Fucini, Kristin M. Zimmerman Savill, Minna Bui, Jennifer N. Hogan, (unknown), Pietro Taverna, Anthony R. Howlett, Margaret E. Flanagan	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact